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Abstract 
Many major structural fetal anomalies can be diagnosed by first trimester fetal anomaly scan. NIPT can accurately 
detect aneuploidies and large chromosomal aberrations in cfDNA in maternal blood plasma. This study shows how a 
patient-friendly first trimester screening for both chromosomal and structural fetal anomalies in only two outpatient 
visits can be provided. Genotype-first approach assures not only the earliest diagnosis of trisomy 21 (the most preva-
lent chromosome aberration), but also completion of the screening at 12–14 weeks. To ensure proper management 
and avoid unnecessary anxiety abnormal NIPT different from trisomy 21, 18 and 13 should be referred for genetic 
counseling.
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First trimester prenatal screening for fetal chromosomal 
aberrations is nowadays challenged by different testing 
options [1]. For more than a decade, the first trimester 
combined test (CT) including Nuchal Translucency (NT) 
measurement was the most sensitive screening test [2], 
but in some countries it is nearly completely replaced 
by the non-invasive prenatal test (NIPT) [3]. This means 
that at this moment in the Netherlands in the majority of 
pregnancies early fetal ultrasound only includes a dating-
scan. This scan is generally performed around the 10th 
gestational week and it is limited to the confirmation of 
fetal viability, determination of gestational age, and in 
case of a multiple pregnancy, to determination of the 
number of viable fetuses and chorionicity. If no appar-
ent major fetal anomaly is noticed during this dating 
scan, current policy is to offer NIPT or CT from the 11th 
gestational week on [3], however only a small minority 
of patients chooses CT. In case of apparent ultrasound 
anomalies or a NT ≥ 3.5 mm an invasive diagnostic test is 
offered instead of NIPT.
The implementation of a first trimester fetal anomaly 
scan (FAS) [4–7] for all pregnant women is due in the 
near future in the Netherlands. When integrating a first 
trimester FAS into the Dutch prenatal screening pro-
gram, several scenarios are possible. Since NIPT can 
be performed from the 10th gestational week, it may 
precede the FAS. Offering NIPT only when the FAS is 
uneventful might be another option as well to prevent 
confusion for pregnant women due to the different test-
ing options. A simple, straightforward clinical scenario 
is needed, in which accessibility and logical consecutive 
investigations with the lowest burden for the patients are 
key-factors. It should also allow early screening and diag-
nosis, important for both patients and the health care 
system. In our experience a pregnant woman prefers a 
diagnosis as early as possible to achieve early reproduc-
tive options and awareness on favorable results. And 
most patients, who choose for either kind of genetic test-
ing (NIPT or microarray), prefer genome-wide analysis 
[3, 8]. So we think that many of them will opt for both 
NIPT and a first trimester FAS. Early screening has a 
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limited time window between 10 and 14 weeks of gesta-
tion, therefore the priorities in this proposal are:
1. as early as possible diagnosis of chromosomal and 
non-chromosomal anomalies,
2. implementation into the routine primary pregnancy 
care and,
3. completion within only two patient visits.
Genotyping first or phenotyping first?
When taking the issues mentioned above into account, 
the most important question that arises is whether 
to perform genotyping or phenotyping as the start-
ing exam. When a patient wishes the earliest possible 
diagnosis, then NIPT, performed from 10  weeks of 
gestation, would be the first test (Fig.  1) in consecu-
tive line. The Dutch TRIDENT studies showed a mean 
reporting time of ~ 6  days, and since the results of 
chorionic villi sampling (CVS) can be achieved within 
1–2 weeks, a final diagnosis is possible between 12 and 
13  weeks gestational age. Moreover, the TRIDENT 
studies showed that the overall technical NIPT fail-
ure rate in the Dutch laboratories is low: 0.3% among 
samples taken from 10 weeks of gestation [9] and 0.2% 
(161/73.239) among samples taken from 11  weeks 
of gestation [3]. Also, the proportion of false nega-
tive results probably due to a low fetal fraction (FF) or 
mosaicism is very low (0.01%—10 cases out of 73 239 
[3]). Therefore, in this setting there is no argument to 
delay NIPT testing after 13–14 weeks for technical rea-
sons. This is confirmed by Wang et al. [10] who showed 
Fig. 1 Integrating NIPT and fetal anomaly scan for efficient and patient-friendly first trimester screening. MCA multiple congenital anomalies
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that the FF raises only 0.1% per week between 10 and 
20 weeks of gestation.
The Dutch TRIDENT 2 study showed that the major-
ity of patients after normal dating scan will receive nor-
mal NIPT results who can then proceed to the FAS. 
In total only 0.75% (550/73239) of patients received 
abnormal NIPT results, either for trisomy 13/18/21 
(343) or other findings (207), which requires refer-
ral for invasive testing (see Fig.  1). So far the uptake 
of NIPT in the Netherlands is moderate, however, it is 
expected to significantly increase if it could be reim-
bursed similar to screening by ultrasound [11, 12]. In 
Dutch settings the expectation is that after subsequent 
FAS, about 0.2–0.3% of patients with normal NIPT 
results will show abnormal FAS outcome [6]. Reiff and 
colleagues found 0.4% structural anomalies or cystic 
hygroma after normal NIPT results (2.1% if NT > 3 mm 
was included) [13]. Therefore we assess that performing 
the ultrasound scan before NIPT will not lead to sub-
stantial cost-effectiveness. Both NIPT and early ultra-
sound detect comparable percentage of aberrant cases 
and each component has an important impact, but 
cannot fully substitute the other. Moreover we believe 
that performing NIPT after FAS will delay the prenatal 
diagnosis of fetal aneuploidies and other chromosomal 
aberrations detectable by NIPT.
The first visit
This first visit in pregnancy (in the Netherlands mostly 
at a community midwife (primary care)) could include 
the dating scan as well as offering pre-test counseling 
for integrated prenatal screening (in our proposal: both 
for NIPT and FAS), followed by a blood sampling if the 
patient chooses to proceed.
Before the second visit, NIPT results are expected to be 
ready:
• When the NIPT results show an increased risk for 
trisomy 13, 18 and 21, the patient should be referred 
for invasive testing (Fig. 1) and a CVS can be offered 
to ensure rapid diagnosis [14].
• Other abnormal NIPT findings should be referred for 
genetic counseling by a dedicated clinical geneticist, 
who closely collaborates with fetal medicine special-
ists, to ensure proper pregnancy management and 
avoid unnecessary anxiety. Appropriate follow up 
testing will depend on the chromosome aberration 
involved [14] and whether the aberration may have a 
maternal or fetal origin.
• In case of normal results: the patient does not need 
to be contacted before the second visit.
The second visit: first trimester FAS and post‑test 
normal NIPT counseling
To make patient’s care pragmatic and lower the social-
economic and health care burden we suggest to integrate 
post-test counseling on normal NIPT results with post-
test counseling after first trimester FAS (Fig. 1).
When NIPT shows a normal result, but the subsequent 
first trimester FAS shows a structural abnormality, the 
patient needs to be referred for an expert ultrasound scan. 
When the fetal anomaly is confirmed, the post-test coun-
seling needs to concentrate on the residual genetic risks: 
both the risk for a false negative NIPT result and the risk for 
genetic anomalies that cannot be detected by current NIPT 
approaches. Invasive testing should be offered. In case of 
multiple congenital anomalies or a suspected genetic syn-
drome patients should subsequently be referred for genetic 
counseling (according to the current standards).
Confirmatory diagnostic testing by CVS
The use of amniocentesis for confirmation of abnormal 
NIPT performed early in pregnancy (at 10–11 weeks of ges-
tation) may lead to an unacceptable long waiting time for the 
prospective parents, since amniocentesis can only be safely 
performed after 15 weeks of gestation. Therefore we previ-
ously explored whether CVS, that can be performed in the 
first trimester of pregnancy, could be a reliable alternative 
for an amniocentesis. It is often believed that CVS and NIPT 
investigate the same placental tissue, and that CVS for NIPT 
confirmation should be avoided. However, whereas NIPT 
investigates the cytotrophoblast of CV, with CVS, another 
cell lineage is investigated, namely the mesenchymal core of 
CV, which has the same embryonic origin as the fetus itself 
(the inner cell mass). Therefore, the latter better reflects the 
chromosomal status of the fetus than the cytotrophoblast, 
which originates from the embryonic trophoblast. However, 
there is a small risk for detecting chromosomal mosaicism 
in the mesenchymal core that potentially is confined to the 
placenta and not present in the fetus (confined placental 
mosaicism, CPM). This will require follow-up diagnostic 
testing of amniotic fluid to differentiate between CPM and 
generalized mosaicism that also affects the fetus. This is a 
limitation of CVS that always should be considered during 
pre-test counseling for any indication. Based on our experi-
ence with cytogenetic investigations in CV and on the lit-
erature, we have previously shown [14], that in the majority 
of cases (97%) CVS can reliably be used for confirmation of 
NIPT positive for trisomy 13, 18, and 21 [14], despite the 
phenomenon of CPM [15]. The risk for a second invasive 
procedure is the smallest in case of trisomy 21 (1.6%), inter-
mediate in case of trisomy 18 (3.2%) and the highest in case 
of trisomy 13 (8.3%). This was confirmed by Grati et al. [16] 
in a large series of CVS. In cases in which NIPT shows an 
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increased risk for trisomy 13, early ultrasound may aid the 
decision on CVS versus amniocentesis.
For other autosomal trisomies that may be detected 
with genome wide NIPT testing, the type of confirma-
tory test (CVS or amniocentesis) will depend on the 
chromosome aberration involved. Of course also other 
factors such as patient preferences, the presence of fetal 
ultrasound anomalies and gestational age will guide the 
choice of invasive procedure [14, 16, 17].
Conclusions
According to this proposal the majority of patients 
(~ 98%) with most favorable results, where both NIPT 
and first trimester FAS are normal, will have com-
pleted the first trimester screening at 11–14  weeks. 
Early prenatal screening and counseling for both chro-
mosomal and major fetal structural anomalies will be 
completed within two outpatient visits. These patients 
can then be offered routine second trimester FAS. Our 
two step early screening proposal combines the aim of 
early diagnosis, offering women early and safe therapy 
options, together with a screening program expected to 
be effective, efficient and patient-friendly.
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